| HIEMX | VEMAX | HIEMX / VEMAX | |
| Total Expense Ratio | 1.23 | 0.13 | 946% |
| Annual Report Gross Expense Ratio | 1.32 | 0.13 | 1,015% |
| Fund Existence | 28 years | 20 years | - |
| Gain YTD | 2.715 | 5.896 | 46% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 100000 | 3000 | 3,333% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 526M | 143B | 0% |
| Annual Yield % from dividends | 1.84 | 2.61 | 70% |
| Returns for 1 year | 22.96 | 31.36 | 73% |
| Returns for 3 years | 7.72 | 45.24 | 17% |
| Returns for 5 years | -37.96 | 16.94 | -224% |
| Returns for 10 years | 7.94 | 121.74 | 7% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BGLD | 18.00 | 0.25 | +1.41% |
| FT Vest Gold Strategy Qt Buffer ETF | |||
| QBER | 23.90 | 0.11 | +0.46% |
| TrueShares Quarterly Bear Hedge ETF | |||
| PBE | 82.76 | 0.02 | +0.02% |
| Invesco Biotechnology & Genome ETF | |||
| IPB | 26.00 | N/A | N/A |
| Merrill Lynch Depositor | |||
| EOS | 22.17 | -0.40 | -1.77% |
| Eaton Vance Enhance Equity Income Fund II | |||